Analysts fell to the sidelines weighing in on Bristol-Myers Squibb (BMY - Research Report) and Agios Pharma (AGIO - Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.

Bristol-Myers Squibb (BMY)

In a report issued on October 31, David Risinger from Leerink Partners maintained a Hold rating on Bristol-Myers Squibb. The company's shares closed last Monday at $55.45, close to its 52-week high of $56.20.

According to TipRanks.com, Risinger is a 5-star analyst with an average return of

The word on The Street in general, suggests a Hold analyst consensus rating for Bristol-Myers Squibb with a $53.79 average price target, a -1.0% downside from current levels. In a report issued on October 17, Bernstein also initiated coverage with a Hold rating on the stock with a $56.00 price target.

According to TipRanks.com, Berens ' ranking currently consits of 0 on a 0-5 ranking scale, with an average return of

Agios Pharma has an analyst consensus of Strong Buy, with a price target consensus of $54.20.